Novel therapeutic agents: Alvimopan, a novel, peripherally-acting, mu-opioid receptor antagonist for the management of opioid-induced bowel dysfunction (OBD): Positive results from a phase III randomized, placebo-controlled, 21-day trial

✍ Scribed by D. Paulson; D. Kennedy; R. Donovick; R. Carpenter; M. Cherubini; L. Techner; W. Du; Y. Ma; W. Schmidt; B. Wallin; D. Jackson

• Book ID: 119305905
• Publisher: Elsevier Science
• Year: 2004
• Tongue: English
• Weight: 54 KB
• Volume: 5
• Category: Article
• ISSN: 1528-8447
• DOI: 10.1016/j.jpain.2004.02.196